Intrinsic Therapeutics Announces the First Implantation of the Barricaid® Annular Closure Device Under Awake Sedation
(NASDAQ:INTR) BOSTON, Sept. 2, 2025 /PRNewswire/ -- Intrinsic Therapeutics, Inc., a medical technology company committed to redefining the standard of care for lumbar discectomy patients with large...
Will this milestone trigger any regulatory updates, insurance coverage changes, or partnerships that could materially impact the stock's valuation?
What is the market's perception of the Barricaid device's competitive advantage versus other annular closure solutions and spine technologies?
How will the first implantation under awake sedation affect Intrinsic Therapeutics' revenue forecast and earnings guidance?
Symbol:
INTR
12 days ago